Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?
作者信息
Song Byung-Cheol
机构信息
Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
出版信息
Clin Mol Hepatol. 2016 Dec;22(4):439-442. doi: 10.3350/cmh.2016.0108. Epub 2016 Dec 25.
Abstract
摘要
相似文献
1
Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination?对于对基于阿德福韦酯的联合治疗反应欠佳的慢性乙型肝炎患者，是转换为基于替诺福韦酯的治疗还是继续基于阿德福韦酯的治疗？
Clin Mol Hepatol. 2016 Dec;22(4):439-442. doi: 10.3350/cmh.2016.0108. Epub 2016 Dec 25.
2
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.恩替卡韦联合替诺福韦与恩替卡韦联合阿德福韦用于对拉米夫定和阿德福韦联合治疗反应欠佳的慢性乙型肝炎患者的疗效比较
Clin Mol Hepatol. 2015 Sep;21(3):242-8. doi: 10.3350/cmh.2015.21.3.242. Epub 2015 Sep 30.
3
Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.阿德福韦酯治疗后病毒学应答不佳的拉米夫定耐药慢性乙型肝炎患者的治疗选择
Aliment Pharmacol Ther. 2011 Oct;34(8):972-81. doi: 10.1111/j.1365-2036.2011.04833.x. Epub 2011 Aug 24.
4
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.替诺福韦酯在拉米夫定耐药的慢性乙型肝炎患者中优于拉米夫定联合阿德福韦酯。
World J Gastroenterol. 2015 Mar 7;21(9):2746-53. doi: 10.3748/wjg.v21.i9.2746.
5
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).对于因对核苷类似物耐药而对基于阿德福韦的联合挽救治疗反应欠佳的慢性乙型肝炎患者，从阿德福韦转换为替诺福韦的疗效（SATIS研究）
Clin Mol Hepatol. 2016 Dec;22(4):443-449. doi: 10.3350/cmh.2016.0037. Epub 2016 Nov 25.
6
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.基于替诺福韦的挽救治疗方案对拉米夫定耐药且拉米夫定与阿德福韦联合治疗失败的慢性乙型肝炎患者的疗效
Clin Ther. 2015 Jul 1;37(7):1433-42. doi: 10.1016/j.clinthera.2015.04.007. Epub 2015 May 5.
7
Tenofovir lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study.替诺福韦酯拉米夫定加阿德福韦酯治疗慢性乙型肝炎：TENOSIMP-B 研究。
World J Gastroenterol. 2017 Nov 7;23(41):7459-7469. doi: 10.3748/wjg.v23.i41.7459.
8
Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.在病毒学抑制的患者中，从拉米夫定+阿德福韦转换为替诺福韦酯的长期疗效和安全性。
Dig Liver Dis. 2017 May;49(5):530-534. doi: 10.1016/j.dld.2017.01.140. Epub 2017 Jan 16.
9
The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.对于对恩替卡韦-阿德福韦联合治疗反应欠佳的患者，基于替诺福韦的治疗疗效。
Clin Mol Hepatol. 2016 Jun;22(2):241-9. doi: 10.3350/cmh.2015.0053. Epub 2016 Jun 15.
10
Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.阿德福韦酯对拉米夫定耐药的乙肝e抗原阴性患者的长期治疗
Aliment Pharmacol Ther. 2008 Feb 1;27(3):266-73. doi: 10.1111/j.1365-2036.2007.03567.x. Epub 2007 Nov 5.
引用本文的文献
1
A Desmethylphosphinothricin Dipeptide Derivative Effectively Inhibits and Growth.一种去甲基膦丝氨酸二肽衍生物能有效抑制 和 生长。
Biomolecules. 2023 Sep 26;13(10):1451. doi: 10.3390/biom13101451.
本文引用的文献
1
Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).对于因对核苷类似物耐药而对基于阿德福韦的联合挽救治疗反应欠佳的慢性乙型肝炎患者，从阿德福韦转换为替诺福韦的疗效（SATIS研究）
Clin Mol Hepatol. 2016 Dec;22(4):443-449. doi: 10.3350/cmh.2016.0037. Epub 2016 Nov 25.
2
Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study.富马酸替诺福韦二吡呋酯（TDF）与恩曲他滨（FTC）/TDF 治疗拉米夫定耐药乙型肝炎：一项 5 年随机研究。
J Hepatol. 2017 Jan;66(1):11-18. doi: 10.1016/j.jhep.2016.08.008. Epub 2016 Aug 18.
3
KASL clinical practice guidelines: management of chronic hepatitis B.KASL临床实践指南：慢性乙型肝炎的管理
Clin Mol Hepatol. 2016 Mar;22(1):18-75. doi: 10.3350/cmh.2016.22.1.18. Epub 2016 Mar 28.
4
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.恩替卡韦联合替诺福韦与恩替卡韦联合阿德福韦用于对拉米夫定和阿德福韦联合治疗反应欠佳的慢性乙型肝炎患者的疗效比较
Clin Mol Hepatol. 2015 Sep;21(3):242-8. doi: 10.3350/cmh.2015.21.3.242. Epub 2015 Sep 30.
5
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance.拉米夫定耐药的阿德福韦酯治疗应答不佳的慢性乙型肝炎患者中应用替诺福韦的挽救治疗。
J Med Virol. 2015 Sep;87(9):1532-8. doi: 10.1002/jmv.24201. Epub 2015 May 4.
6
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.阿德福韦耐药慢性乙型肝炎患者多药耐药时单用替诺福韦与替诺福韦联合恩替卡韦治疗的随机试验结果。
Gut. 2016 Jun;65(6):1042-51. doi: 10.1136/gutjnl-2014-308435. Epub 2015 Mar 23.
7
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.替诺福韦酯在拉米夫定耐药的慢性乙型肝炎患者中优于拉米夫定联合阿德福韦酯。
World J Gastroenterol. 2015 Mar 7;21(9):2746-53. doi: 10.3748/wjg.v21.i9.2746.
8
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.替诺福韦单药治疗与替诺福韦和恩替卡韦联合治疗对多种药物耐药的慢性乙型肝炎患者：一项随机试验的结果。
Gut. 2016 May;65(5):852-60. doi: 10.1136/gutjnl-2014-308353. Epub 2015 Jan 16.
9
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection.替诺福韦酯治疗慢性乙型肝炎病毒感染的七年疗效与安全性
Dig Dis Sci. 2015 May;60(5):1457-64. doi: 10.1007/s10620-014-3486-7. Epub 2014 Dec 23.
10
Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.拉米夫定耐药慢性乙型肝炎患者接受阿德福韦单药治疗期间，阿德福韦耐药突变病毒的不同选择机制。
Antiviral Res. 2014 Dec;112:8-17. doi: 10.1016/j.antiviral.2014.09.013. Epub 2014 Oct 7.
Zotero 插件